CD261 (DR4) Monoclonal Antibody (DJR1), PE, eBioscience | Invitrogen 12-6644-41 product information

product summary

company name :

Invitrogen

other brands :

NeoMarkers, Lab Vision, Endogen, Pierce, BioSource International, Zymed Laboratories, Caltag, Molecular Probes, Research Genetics, Life Technologies, Applied Biosystems, GIBCO BRL, ABgene, Dynal, Affinity BioReagents, Nunc, Invitrogen, NatuTec, Oxoid, Richard-Allan Scientific, Arcturus, Perseptive Biosystems, Proxeon, eBioscience

product type :

antibody

product name :

CD261 (DR4) Monoclonal Antibody (DJR1), PE, eBioscience

catalog :

12-6644-41

quantity :

25 Tests

price :

US 163

clonality :

monoclonal

host :

mouse

conjugate :

clone name :

DJR1

reactivity :

human

application :

flow cytometry

more info or order :

Invitrogen product webpage

citations: 36

Published Application/Species/Sample/Dilution	Reference
flow cytometry; human; fig 4c	Fauster A, Rebsamen M, Willmann K, César Razquin A, Girardi E, Bigenzahn J, et al. Systematic genetic mapping of necroptosis identifies SLC39A7 as modulator of death receptor trafficking. Cell Death Differ. 2019;26:1138-1155 pubmed publisher
flow cytometry; human; fig s2	Liesche C, Venkatraman L, Aschenbrenner S, Grosse S, Grimm D, Eils R, et al. Death receptor-based enrichment of Cas9-expressing cells. BMC Biotechnol. 2016;16:17 pubmed publisher
flow cytometry; human	Linderoth E, Pilia G, Mahajan N, Ferby I. Activated Cdc42-associated kinase 1 (Ack1) is required for tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) receptor recruitment to lipid rafts and induction of cell death. J Biol Chem. 2013;288:32922-31 pubmed publisher
	Ivanov V, Wu J, Hei T. Regulation of human glioblastoma cell death by combined treatment of cannabidiol, ?-radiation and small molecule inhibitors of cell signaling pathways. Oncotarget. 2017;8:74068-74095 pubmed publisher
	Milutinovic S, Kashyap A, Yanagi T, Wimer C, Zhou S, O Neil R, et al. Dual Agonist Surrobody Simultaneously Activates Death Receptors DR4 and DR5 to Induce Cancer Cell Death. Mol Cancer Ther. 2016;15:114-24 pubmed publisher
	Hwang M, Li X, Kim J, Jeong S, Lee S, Lee J, et al. Potential Therapeutic Effect of Natural Killer Cells on Doxorubicin-Resistant Breast Cancer Cells In Vitro. PLoS ONE. 2015;10:e0136209 pubmed publisher
	Chandrasekaran S, Marshall J, Messing J, Hsu J, King M. TRAIL-mediated apoptosis in breast cancer cells cultured as 3D spheroids. PLoS ONE. 2014;9:e111487 pubmed publisher
	Redjal N, Zhu Y, Shah K. Combination of systemic chemotherapy with local stem cell delivered S-TRAIL in resected brain tumors. Stem Cells. 2015;33:101-10 pubmed publisher
	Boyko Fabian M, Niehr F, Distel L, Budach V, Tinhofer I. Increased growth-inhibitory and cytotoxic activity of arsenic trioxide in head and neck carcinoma cells with functional p53 deficiency and resistance to EGFR blockade. PLoS ONE. 2014;9:e98867 pubmed publisher
	Turner A, Li L, Pilli T, Qian L, Wiley E, Setty S, et al. MADD knock-down enhances doxorubicin and TRAIL induced apoptosis in breast cancer cells. PLoS ONE. 2013;8:e56817 pubmed publisher
	Zhang N, Wang X, Huo Q, Li X, Wang H, Schneider P, et al. The oncogene metadherin modulates the apoptotic pathway based on the tumor necrosis factor superfamily member TRAIL (Tumor Necrosis Factor-related Apoptosis-inducing Ligand) in breast cancer. J Biol Chem. 2013;288:9396-407 pubmed publisher
	Bagci Onder T, Agarwal A, Flusberg D, Wanningen S, Sorger P, Shah K. Real-time imaging of the dynamics of death receptors and therapeutics that overcome TRAIL resistance in tumors. Oncogene. 2013;32:2818-27 pubmed publisher
	Kajitani K, Tanaka Y, Arihiro K, Kataoka T, Ohdan H. Mechanistic analysis of the antitumor efficacy of human natural killer cells against breast cancer cells. Breast Cancer Res Treat. 2012;134:139-55 pubmed publisher
	Li Z, Peng H, Xu Q, Ye Z. Sensitization of human osteosarcoma cells to V?9V?2 T-cell-mediated cytotoxicity by zoledronate. J Orthop Res. 2012;30:824-30 pubmed publisher
	Dompe N, Rivers C, Li L, Cordes S, Schwickart M, Punnoose E, et al. A whole-genome RNAi screen identifies an 8q22 gene cluster that inhibits death receptor-mediated apoptosis. Proc Natl Acad Sci U S A. 2011;108:E943-51 pubmed publisher
	Dhandapani L, Yue P, Ramalingam S, Khuri F, Sun S. Retinoic acid enhances TRAIL-induced apoptosis in cancer cells by upregulating TRAIL receptor 1 expression. Cancer Res. 2011;71:5245-54 pubmed publisher
	Hanada K, Wang Q, Inozume T, Yang J. Molecular identification of an MHC-independent ligand recognized by a human {alpha}/{beta} T-cell receptor. Blood. 2011;117:4816-25 pubmed publisher
	Fu L, Lin Y, Elrod H, Yue P, Oh Y, Li B, et al. c-Jun NH2-terminal kinase-dependent upregulation of DR5 mediates cooperative induction of apoptosis by perifosine and TRAIL. Mol Cancer. 2010;9:315 pubmed publisher
	Cabezón R, Sintes J, Llinàs L, Benitez Ribas D. Analysis of HLDA9 mAbs on plasmacytoid dendritic cells. Immunol Lett. 2011;134:167-73 pubmed publisher
	Bisgin A, Terzioglu E, Aydin C, Yoldas B, Yazisiz V, Balci N, et al. TRAIL death receptor-4, decoy receptor-1 and decoy receptor-2 expression on CD8+ T cells correlate with the disease severity in patients with rheumatoid arthritis. BMC Musculoskelet Disord. 2010;11:192 pubmed publisher
	Nagane M, Shimizu S, Mori E, Kataoka S, Shiokawa Y. Predominant antitumor effects by fully human anti-TRAIL-receptor 2 (DR5) monoclonal antibodies in human glioma cells in vitro and in vivo. Neuro Oncol. 2010;12:687-700 pubmed publisher
	Balsas P, López Royuela N, Galán Malo P, Anel A, Marzo I, Naval J. Cooperation between Apo2L/TRAIL and bortezomib in multiple myeloma apoptosis. Biochem Pharmacol. 2009;77:804-12 pubmed publisher
	Song J, Kandasamy K, Kraft A. ABT-737 induces expression of the death receptor 5 and sensitizes human cancer cells to TRAIL-induced apoptosis. J Biol Chem. 2008;283:25003-13 pubmed publisher
	Lin Y, Chen S, Yue P, Zou W, Benbrook D, Liu S, et al. CAAT/enhancer binding protein homologous protein-dependent death receptor 5 induction is a major component of SHetA2-induced apoptosis in lung cancer cells. Cancer Res. 2008;68:5335-44 pubmed publisher
	Hyer M, Shi R, Krajewska M, Meyer C, Lebedeva I, Fisher P, et al. Apoptotic activity and mechanism of 2-cyano-3,12-dioxoolean-1,9-dien-28-oic-acid and related synthetic triterpenoids in prostate cancer. Cancer Res. 2008;68:2927-33 pubmed publisher
	Verbrugge I, de Vries E, Tait S, Wissink E, Walczak H, Verheij M, et al. Ionizing radiation modulates the TRAIL death-inducing signaling complex, allowing bypass of the mitochondrial apoptosis pathway. Oncogene. 2008;27:574-84 pubmed
	Liu X, Yue P, Chen S, Hu L, Lonial S, Khuri F, et al. The proteasome inhibitor PS-341 (bortezomib) up-regulates DR5 expression leading to induction of apoptosis and enhancement of TRAIL-induced apoptosis despite up-regulation of c-FLIP and survivin expression in human NSCLC cells. Cancer Res. 2007;67:4981-8 pubmed
	Qiu Y, Liu X, Zou W, Yue P, Lonial S, Khuri F, et al. The farnesyltransferase inhibitor R115777 up-regulates the expression of death receptor 5 and enhances TRAIL-induced apoptosis in human lung cancer cells. Cancer Res. 2007;67:4973-80 pubmed
	Sun S, Liu X, Zou W, Yue P, Marcus A, Khuri F. The farnesyltransferase inhibitor lonafarnib induces CCAAT/enhancer-binding protein homologous protein-dependent expression of death receptor 5, leading to induction of apoptosis in human cancer cells. J Biol Chem. 2007;282:18800-9 pubmed
	Vanoosten R, Earel J, Griffith T. Histone deacetylase inhibitors enhance Ad5-TRAIL killing of TRAIL-resistant prostate tumor cells through increased caspase-2 activity. Apoptosis. 2007;12:561-71 pubmed
	Song J, Bellail A, Tse M, Yong V, Hao C. Human astrocytes are resistant to Fas ligand and tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis. J Neurosci. 2006;26:3299-308 pubmed
	VanOosten R, Earel J, Griffith T. Enhancement of Ad5-TRAIL cytotoxicity against renal cell carcinoma with histone deacetylase inhibitors. Cancer Gene Ther. 2006;13:628-32 pubmed
	Ishiyama K, Ohdan H, Ohira M, Mitsuta H, Arihiro K, Asahara T. Difference in cytotoxicity against hepatocellular carcinoma between liver and periphery natural killer cells in humans. Hepatology. 2006;43:362-72 pubmed
	Earel J, Vanoosten R, Griffith T. Histone deacetylase inhibitors modulate the sensitivity of tumor necrosis factor-related apoptosis-inducing ligand-resistant bladder tumor cells. Cancer Res. 2006;66:499-507 pubmed
	Hyer M, Croxton R, Krajewska M, Krajewski S, Kress C, Lu M, et al. Synthetic triterpenoids cooperate with tumor necrosis factor-related apoptosis-inducing ligand to induce apoptosis of breast cancer cells. Cancer Res. 2005;65:4799-808 pubmed
	Zou W, Liu X, Yue P, Zhou Z, Sporn M, Lotan R, et al. c-Jun NH2-terminal kinase-mediated up-regulation of death receptor 5 contributes to induction of apoptosis by the novel synthetic triterpenoid methyl-2-cyano-3,12-dioxooleana-1, 9-dien-28-oate in human lung cancer cells. Cancer Res. 2004;64:7570-8 pubmed

product information

Product Type :

Antibody

Product Name :

CD261 (DR4) Monoclonal Antibody (DJR1), PE, eBioscience

Catalog # :

12-6644-41

Quantity :

25 Tests

Pricing :

US 163

Clonality :

Monoclonal

Purity :

Affinity chromatography

Host :

Mouse

Reactivity :

Human

Applications :

Flow Cytometry: 5 µL (0.5 µg)/test

Species :

Human

Clone :

DJR1

Isotype :

IgG1, kappa

Storage :

4° C, store in dark, DO NOT FREEZE!

Description :

TRAIL-R1 (CD261, DR4) is a type I transmembrane protein, also called TRAIL receptor 1. The ligand for this DR4 death receptor has been identified and termed TRAIL, which is a member of the TNF family. DR4, as many other receptors (Fas, TNFR1, etc.), mediates apoptosis and NF kappaB activation in many cells and tissues. Apoptosis, a programmed cell death, is a operating process in normal cellular differentiation and development of multicellular organisms. Apoptosis is induced by coupled of certain cytokines (TNF family - TNF, Fas ligand) and their death domain containing receptors (TNFR1, Fas receptor).

Format :

Liquid

Applications w/Dilutions :

Flow Cytometry: 5 µL (0.5 µg)/test

Aliases :

APO2; CD261; cytotoxic TRAIL receptor; death receptor 4; DR4; MGC9365; sCD261; soluble CD261; soluble TRAIL; sTRAIL; TNF receptor superfamily member 10a; TNF-related apoptosis-inducing ligand receptor 1; TNFRSF10A; TRAIL R1; TRAIL receptor 1; TRAILR1; TRAIL-R1; TRAILR-1; tumor necrosis factor receptor superfamily member 10A; tumor necrosis factor receptor superfamily member 10a variant 2; tumor necrosis factor receptor superfamily, member 10a

more info or order :

Invitrogen product webpage